Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Enterovirus Type 71 Vaccine in Healthy Children
NCT07793175Not yet recruiting
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of inactivated EV71 vaccine in HIV-associated central nervous system involvement (HAND) and enterovirus 71 infection, sponsored by Sinovac Biotech Ltd. Primary endpoint: Seroconversion rate of Enterovirus Type 71 (EV71) neutralizing antibodies. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
inactivated EV71 vaccine
03
Conditions
HIV-associated central nervous system involvement (HAND)enterovirus 71 infection
Beyond the preview
Go deeper on NCT07793175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793175.